Broad molecule growth increased sales
Quarterly revenue changed from 247.1 ₹ crore (Q2 FY26) to 309.1 ₹ crore (Q2 FY27). Broad molecule growth increased sales.
Watch: Track repeat orders
Home / Research / Concord Biotech Limited
Broad molecule growth increased sales
Quarterly revenue changed from 247.1 ₹ crore (Q2 FY26) to 309.1 ₹ crore (Q2 FY27). Broad molecule growth increased sales.
Watch: Track repeat orders
Quarterly EBITDA changed from 88.5 ₹ crore (Q2 FY26) to 104.4 ₹ crore (Q2 FY27). Profit grew slower than sales.
Watch: Inspect product mix
Quarterly PAT changed from 63.1 ₹ crore (Q2 FY26) to 69.6 ₹ crore (Q2 FY27). PAT rose about 10%.
Watch: Check taxes
Half-year revenue changed from 451.1 ₹ crore (H1 FY26) to 566.6 ₹ crore (H1 FY27). H1 revenue rose 26%.
Watch: Compare similar period
Quarter ended 30 September 2026 · Stance WATCH · original issuer/exchange sources. Concord Biotech offers differentiated fermentation and specialty pharma product exposure, but its quarter illustrates that sales growth is not identical to earnings growth. Revenue rose roughly 25% to ₹309.1 crore, EBITDA about 18% to ₹104.4 crore and PAT about 10% to ₹69.6 crore. WATCH, contingent on regulatory delivery, repeat orders and sustainable margin, not unverified valuation or product-pipeline multiples. [S1][S2]
| Decision metric | Earlier reference | Latest reference |
|---|---|---|
| Quarterly revenue | 247.1 ₹ crore (Q2 FY26) | 309.1 ₹ crore (Q2 FY27) |
| Quarterly EBITDA | 88.5 ₹ crore (Q2 FY26) | 104.4 ₹ crore (Q2 FY27) |
| Quarterly PAT | 63.1 ₹ crore (Q2 FY26) | 69.6 ₹ crore (Q2 FY27) |
| Half-year revenue | 451.1 ₹ crore (H1 FY26) | 566.6 ₹ crore (H1 FY27) |
| Half-year EBITDA | 149.9 ₹ crore (H1 FY26) | 186.8 ₹ crore (H1 FY27) |
| Half-year PAT | 107.1 ₹ crore (H1 FY26) | 127.3 ₹ crore (H1 FY27) |
| Derived quarterly EBITDA margin | 35.8 % (Q2 FY26) | 33.8 % (Q2 FY27) |
| Q2 growth comparison | 25 % YoY (Revenue) | 18 % YoY (EBITDA) |
Key takeaways: Quarterly revenue: Broad molecule growth increased sales. Quarterly EBITDA: Profit grew slower than sales. Quarterly PAT: PAT rose about 10%. Half-year revenue: H1 revenue rose 26%. Half-year EBITDA: H1 EBITDA rose 25%. Half-year PAT: H1 PAT grew 19%. All comparisons follow the issuer's specified dates, basis and units. The separate graphical Investment Briefing precedes the detailed main report.
Concord Biotech offers differentiated fermentation and specialty pharma product exposure, but its quarter illustrates that sales growth is not identical to earnings growth. Revenue rose roughly 25% to ₹309.1 crore, EBITDA about 18% to ₹104.4 crore and PAT about 10% to ₹69.6 crore. WATCH, contingent on regulatory delivery, repeat orders and sustainable margin, not unverified valuation or product-pipeline multiples. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Broad molecule growth increased sales. The practical next-quarter test is: track repeat orders. Profit grew slower than sales. The practical next-quarter test is: inspect product mix. PAT rose about 10%. The practical next-quarter test is: check taxes. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
The issuer presented consolidated Q2 revenue ₹309.1 crore versus ₹247.1 crore, EBITDA ₹104.4 crore versus ₹88.5 crore and PAT ₹69.6 crore versus ₹63.1 crore. H1 revenue ₹566.6 crore versus ₹451.1 crore, H1 EBITDA ₹186.8 crore versus ₹149.9 crore, and H1 PAT ₹127.3 crore versus ₹107.1 crore show six-month growth. Derived Q2 EBITDA margin around 33.8% compared with 35.8% is based on rounded figures, not a separately certified financial statement measure. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. PAT rose about 10%. The practical next-quarter test is: check taxes. H1 revenue rose 26%. The practical next-quarter test is: compare similar period. H1 EBITDA rose 25%. The practical next-quarter test is: test recurring margin. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
Immunosuppressants, anti-infectives, antifungals and oncology products drive a regulated molecule portfolio. Management described growth across categories and geographies, broader wallet share from current customers and advanced discussions with new clients. New customer qualification takes time and may require formulation, manufacturing and regulatory investment. Product breadth helps mitigate concentration but can also change operating margin; a pipeline is not booked sales. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. H1 EBITDA rose 25%. The practical next-quarter test is: test recurring margin. H1 PAT grew 19%. The practical next-quarter test is: validate cash conversion. Calculated margin reduced by ~2 points. The practical next-quarter test is: check audited ratio. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
The presentation described a USFDA inspection of formulation Unit II at Valthera, Ahmedabad with one procedural observation characterized as unrelated to GMP. It referenced approvals of tofacitinib and mycophenolate mofetil oral suspension. The newly launched Inspira dermatology division is an extension of the commercial platform, not yet proof of durable earnings. Management's target to introduce two or three products a year is an aspiration requiring actual approval, manufacturing and launch evidence. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Calculated margin reduced by ~2 points. The practical next-quarter test is: check audited ratio. Sales growth outpaced EBITDA. The practical next-quarter test is: isolate mix. Profit conversion was weaker. The practical next-quarter test is: review below-operating costs. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
Regulated pharma commercialization relies on working capital, validation, production yields and stability of customer orders. A one-for-one bonus issue changes the share denominator but does not generate operating cash. The accepted Q2 results do not establish a complete audited project capex, debt or free-cash-flow bridge, so no leveraged-valuation input should be invented. Investors should look for the next cash-flow statement and launch economics to validate the stated investment narrative. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Profit conversion was weaker. The practical next-quarter test is: review below-operating costs. H1 profit almost matched sales. The practical next-quarter test is: review second half. Net earnings rose less than EBITDA. The practical next-quarter test is: review tax. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
Bull: continued double-digit growth with sustained regulatory compliance, repeat exports and a recovery in product mix margin. Base: broad growth continues but new approvals and new-division investments hold profit growth below sales growth. Bear: quality issues, slow regulatory approvals, pricing pressure or poor unit utilization reduce cash conversion. These conditional cases are monitoring disciplines, not claimed probabilities or stock-price returns. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. Broad molecule growth increased sales. The practical next-quarter test is: track repeat orders. Profit grew slower than sales. The practical next-quarter test is: inspect product mix. PAT rose about 10%. The practical next-quarter test is: check taxes. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
WATCH quarterly revenue ₹309.1 crore, EBITDA ₹104.4 crore and PAT ₹69.6 crore with explicit Q2 FY26 comparators. Track Unit II compliance, actual product launches, net customer additions and repeat-orders, plus H1 revenue ₹566.6 crore against period-matched prior data. Strengthen conviction only when new business translates into recurring after-tax cash and a verified valuation permits margin-of-safety analysis. [S1][S2]
Issuer-specific financial checks and decisions
Monitoring interpretation. PAT rose about 10%. The practical next-quarter test is: check taxes. H1 revenue rose 26%. The practical next-quarter test is: compare similar period. H1 EBITDA rose 25%. The practical next-quarter test is: test recurring margin. These observations help distinguish underlying operating economics from stated management ambitions; they do not establish an unreported entry price, dividend, free cash flow or earnings forecast.
[S1] Concord Biotech Limited Q2 FY27 earnings-call transcript — management discussion and analyst questions for the September 2026 quarter. [S2] — issuer financial and operating data.
Interpretive limits: Future product launches, order contracts, customer discussions, raw-material effects and project milestones are cited as management commentary where relevant, not realized future profits. Valuation figures, project payback, market prices, leverage and cash conversions are omitted where the saved issuer evidence is inadequate.
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.